Evidence map›Paper›PMID 41495773›Full record

ArticleJournal of nanobiotechnology2026

In-situ ²²³Ra-doped calcium-alginate composite microspheres: a high-LET and immunoactivating platform for α-particle radioembolization in hepatocellular carcinoma.

Jinming Tian, Zeyu Zhang, Chao Cheng, Fei Yu, Tao Wang, Bin Cui, Ye Peng, Shuang Qiu, Fuming Wang, Weijing Cheng and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jinming Tian *Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
Zeyu Zhang *Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
Chao Cheng *Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
Fei YuDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, P. R. China.
Tao WangDepartment of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
Bin CuiDepartment of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
Ye PengDepartment of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
Shuang QiuDepartment of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
Fuming WangDepartment of Interventional Radiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
Weijing ChengDepartment of Interventional Radiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
Rong LuoDepartment of Interventional Radiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
Guorong JiaDepartment of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China. jiaguorong79@163.com.
Changjing ZuoDepartment of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China. changjing.zuo@qq.com.

Funding

Major Research Plan of National Natural Science Foundation of China No. 92359204Medical Research Project of Shanghai Hongkou District Health Commission No. 2303-23National Natural Science Foundation of China No. 82272040National Natural Science Foundation of China No. 82302247Shanghai Pujiang Program No. 22PJD014
6 · The paper itself

Abstract

Transarterial radioembolization (TARE) with β-emitting radionuclides is widely used for hepatocellular carcinoma (HCC), but its clinical efficacy remains to be further improved. α-particle-emitting radionuclides possess high linear energy transfer (LET) and unique advantages in cancer therapy, motivating α-particle based composite platform. Accordingly, we engineer the first clinically mimetic α-TARE microsphere by in-situ ²²³Ra-doped calcium-alginate composite microsphere (²²³Ra/Ca-ALG MS) using a hydrogel matrix, in which alginate "egg-box" coordination captures Ra²⁺ to provide stable radiolabeling, delivered via selective hepatic arterial injection to HCC. The microspheres exhibited excellent radiolabeling stability (88% retention after 384 h) and potent, dose-dependent cytotoxicity against HCC cells under hypoxia. In an orthotopic rat HCC model,

Indexed as

AlginatesAlpha ParticlesCalciumCarcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsMicrospheresRadiumAnimalsCell Line, TumorGlucuronic AcidHexuronic AcidsHumansMaleRadiopharmaceuticalsRatsAlginatesCalciumGlucuronic AcidHexuronic AcidsRadiopharmaceuticalsRadiumRadium-223Calcium alginate microsphereHepatocellular carcinomaImmunotherapyRadium-223Transarterial radioembolization

Identifiers

PMID41495773
PMCPMC12869965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.